Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
7 studies found for:    22508812 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)
Condition: Breast Cancer
Intervention: Drug: Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab
2 Completed Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)
Condition: Breast Cancer
Interventions: Drug: Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa;   Drug: Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa
3 Completed Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer
Condition: Primary Breast Cancer
Interventions: Drug: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen;   Drug: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
4 Completed Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Drug: capecitabine;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: epirubicin hydrochloride;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy
5 Recruiting Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Neoadjuvant endocrine therapy;   Drug: Neoadjuvant chemotherapy
6 Recruiting A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Conditions: Breast Cancer;   Hormonreceptor Positive;   Her2-normal;   Postneoadjuvant Treatment With CDK 4/6 Inhibitor;   CPS-EG Score
Interventions: Drug: Palbociclib PD-0332991;   Drug: Placebo
7 Completed Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer
Condition: Breast Cancer
Interventions: Drug: TAC;   Drug: NX

Study has passed its completion date and status has not been verified in more than two years.